A Phase 2B Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of 3 Dosages of SAP-001 in Combination With Standard of Care in Adult Subjects With Gout
Latest Information Update: 22 May 2025
At a glance
- Drugs SAP 001 (Primary)
- Indications Gout; Gouty arthritis
- Focus Therapeutic Use
- Acronyms RID-GOUT
- Sponsors Shanton Pharma
Most Recent Events
- 19 May 2025 According to a Shanton Pharma media release, company will be presenting topline data from this study at the annual EULAR Congress in Barcelona on June 14.
- 28 Mar 2025 Topline results presented in the Shanton Pharma Media Release
- 14 Nov 2024 Planned End Date changed from 30 Jan 2025 to 1 Feb 2025.